Lindauer M, Fischer T
3rd Medical Department, Johannes Gutenberg-University, Mainz, Germany.
Leuk Lymphoma. 2001 May;41(5-6):523-33. doi: 10.3109/10428190109060343.
During the last decade, several studies have evaluated the treatment of chronic phase chronic myeloid leukemia (CML) with a combination of interferon (IFN)-alpha and low- dose cytarabine (Ara-C). This combination therapy has been shown to be superior compared to monotherapy with IFN-alpha in randomized studies with regard to hematologic and cytogenetic remissions. However, the survival benefit is small, and the toxicity of the combination therapy is high. This paper reviews the published studies on IFN-alpha/low-dose Ara-C for the treatment of chronic phase CML and discusses the value of the combination therapy.
在过去十年中，多项研究评估了干扰素（IFN）-α与小剂量阿糖胞苷（Ara-C）联合治疗慢性期慢性髓性白血病（CML）的效果。在随机研究中，就血液学和细胞遗传学缓解而言，这种联合疗法已被证明优于IFN-α单药治疗。然而，生存获益较小，且联合疗法的毒性较高。本文综述了已发表的关于IFN-α/小剂量Ara-C治疗慢性期CML的研究，并讨论了联合疗法的价值。
